Halozyme Therapeutics
HALO
$103.12
+20.24%
Halozyme Therapeutics, Inc. is a biotechnology company specializing in the development and commercialization of oncology therapies, with a core focus on its proprietary ENHANZE drug delivery technology that enables subcutaneous administration of injectable drugs. The company operates as a hybrid model, both developing its own products and licensing its technology to major biopharmaceutical partners, positioning it as a key enabler in the industry. Currently, the investment narrative centers on the robust growth of royalty revenues from partnered products, particularly with the expansion of ENHANZE into high-volume indications, and the company's ability to sustain double-digit revenue growth while maintaining exceptional profitability. Recent attention has also been drawn to the company's strong cash flow generation and its strategic capital allocation, including share repurchases, as it balances growth investments with shareholder returns.…
HALO
Halozyme Therapeutics
$103.12
Investment Opinion: Should I buy HALO Today?
Based on the analysis, HALO is rated a Buy. The company's strong revenue growth (42% YoY), exceptional profitability (71% gross margin), and low forward PE (8.6x) relative to growth indicate that the stock is undervalued. The consensus analyst rating is 'Buy' with an average target price of $86.89, implying a modest 1.3% upside, but the potential for earnings growth could drive the stock higher. Key supporting data points include: revenue of $376.7 million in Q1 2026, up 42.2% YoY; operating margin of 58.4%; free cash flow of $176.3 million in Q1; and a forward PE of 8.6x versus the industry average. The main risks are the concentration in royalty revenue and the possibility of one-time charges. This Buy rating would be upgraded if the forward PE compresses below 7x or if revenue growth accelerates above 50%, while a downgrade to Hold would occur if growth decelerates below 20% or if the stock price exceeds the high target of $96. Overall, HALO appears undervalued relative to its growth prospects.
Sign up to view all
HALO 12-Month Price Forecast
The AI assessment is bullish on HALO, driven by its exceptional growth metrics and undervaluation. The forward PE of 8.6x is remarkably low for a company with 42% revenue growth, suggesting the market is not fully pricing in future earnings potential. The strong free cash flow and solid balance sheet provide a cushion for downside. However, the medium confidence reflects the uncertainty around royalty revenue concentration and the modest analyst target upside. If the company continues to deliver on growth and expands its partnership pipeline, the stock could re-rate higher. A downgrade to neutral would occur if revenue growth falls below 20% or if there is a significant negative event in a key partnership.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Halozyme Therapeutics's 12-month outlook, with a consensus price target around $97.33 and implied upside of -5.6% versus the current price.
Average Target
$97.33
0 analysts
Implied Upside
-5.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$70 - $115
Analyst target range
Halozyme is covered by 9 analysts, with a consensus recommendation of 'Buy' and a mean rating of 1.89 (where 1 is Strong Buy and 5 is Sell). The average target price is $86.89, which is 1.3% above the current price of $85.76, implying a modest upside. The distribution includes 6 Buy ratings, 2 Hold, and 1 Sell, indicating a generally bullish but not overly enthusiastic sentiment. The target price range spans from a low of $70.00 to a high of $96.00, with the high target representing 11.9% upside and the low target implying 18.4% downside. The wide spread of $26 suggests significant uncertainty about the company's future performance, likely due to the variability in royalty revenue and the success of partnered drugs. Recent institutional ratings have been stable, with no major upgrades or downgrades in the past six months, as firms like Morgan Stanley, HC Wainwright, and Benchmark maintain their Overweight/Buy ratings, while Goldman Sachs and JP Morgan hold Neutral stances. The consensus target price reflects a balanced view, with the average close to the current price, indicating that analysts see fair value near current levels but with potential for upside if growth accelerates.
Drowning in data?
Find the real signal!
Bulls vs Bears: HALO Investment Factors
Halozyme presents a compelling growth story with accelerating revenue (42% YoY), exceptional margins (71% gross), and a low forward PE (8.6x) that suggests undervaluation. However, the modest analyst target upside (1.3%) and the risk of one-time charges like the Q4 2025 impairment temper enthusiasm. The bull case is currently stronger, driven by robust fundamentals and growth prospects, but the key tension lies in whether the company can sustain its high growth rate and convert it into earnings that justify the current valuation. If growth decelerates or partnerships falter, the stock could face multiple compression, while continued execution could lead to significant upside.
Bullish
- Revenue growth accelerating to 42% YoY: Q1 2026 revenue of $376.7 million grew 42.2% year-over-year, up from 20%+ growth in prior quarters, driven by strong royalty and product sales from ENHANZE-enabled therapies like DARZALEX. This acceleration indicates robust demand and successful commercialization of partnered products.
- Exceptional profitability with 71% gross margin: Gross margin of 71.1% and operating margin of 58.4% in Q1 2026 reflect the high-margin nature of the ENHANZE licensing model. Net income of $150 million (39.8% net margin) demonstrates strong earnings power and scalability.
- Forward PE of 8.6x implies undervaluation: With a forward PE of 8.6x versus trailing PE of 25.5x, the market expects significant earnings growth. For a company growing revenue at 42%, this low forward multiple suggests the stock is undervalued relative to its growth prospects, offering potential upside.
- Strong free cash flow generation: Q1 2026 free cash flow was $176.3 million, with TTM FCF of $667.7 million. This cash generation supports share repurchases and strategic investments, enhancing shareholder value without relying on external financing.
Bearish
- Q4 2025 net loss of -$141.6 million: A one-time impairment in Q4 2025 led to a net loss of -$141.6 million, highlighting the risk of non-cash charges that can distort earnings. While underlying profitability is strong, such charges could recur and impact investor sentiment.
- Analyst target upside limited to 1.3%: The average analyst target price of $86.89 is only 1.3% above the current price of $85.76, suggesting limited near-term upside. This indicates that analysts see fair value near current levels, capping potential gains.
- High valuation on trailing PE of 25.5x: The trailing PE of 25.5x is elevated compared to the broader market, and the stock's historical PE range (6.6x to 68.8x) shows volatility. If growth decelerates, the multiple could compress, leading to price declines.
- Concentration risk in royalty revenue: Royalties ($240.7 million) and product sales ($265.8 million) dominate revenue, with a heavy reliance on partnered products like DARZALEX. Any setback in these partnerships or patent expirations could significantly impact revenue.
HALO Technical Analysis
Halozyme's stock is in a clear uptrend, with a 1-year price change of +37.6% and the current price of $85.76 sitting just 0.3% below its 52-week high of $86.00, while being 40.1% above its 52-week low of $61.23. This positioning near the upper end of the range indicates strong momentum and investor confidence, though it also suggests the stock may be susceptible to short-term overextension. The 6-month price change of +5.6% is modest compared to the 1-year gain, but the recent acceleration in the last three months (+33.7%) shows renewed buying interest.
Beta
0.85
0.85x market volatility
Max Drawdown
-24.1%
Largest decline past year
52-Week Range
$61-$103
Price range past year
Annual Return
+66.1%
Cumulative gain past year
| Period | HALO Return | S&P 500 |
|---|---|---|
| 1m | +28.3% | +2.4% |
| 3m | +60.8% | +4.6% |
| 6m | +26.9% | +11.7% |
| 1y | +66.1% | +21.4% |
| ytd | +46.7% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HALO Fundamental Analysis
Halozyme's revenue trajectory is robustly growing, with Q1 2026 revenue of $376.7 million, up 42.2% year-over-year, and a sequential increase from $325.7 million in Q2 2025. The revenue mix is heavily weighted toward royalties ($240.7 million) and product sales ($265.8 million), with collaborative agreements contributing $5.6 million, indicating a diversified but royalty-driven model. This growth is accelerating, as the YoY growth rate in Q1 2026 (42.2%) exceeds the 20%+ growth seen in earlier quarters, driven by strong performance of partnered products like DARZALEX and other ENHANZE-enabled therapies. The company's profitability is exceptional, with a gross margin of 71.1% in Q1 2026 and an operating margin of 58.4%, reflecting the high-margin nature of its technology licensing and royalty streams. Net income for Q1 2026 was $150.0 million, a net margin of 39.8%, and while Q4 2025 showed a net loss of -$141.6 million due to a one-time impairment, the underlying profitability trend is strong. The balance sheet is solid, with a current ratio of 4.66 and a debt-to-equity ratio of 43.9%, indicating manageable leverage. Free cash flow for Q1 2026 was $176.3 million, and TTM FCF is $667.7 million, providing ample cash to fund operations and buybacks. ROE is 6.49% (though this is distorted by the large equity base), and the company has no dividend, preferring to reinvest in growth and repurchases.
Quarterly Revenue
$376708000.0B
2026-03
Revenue YoY Growth
+42.2%
YoY Comparison
Gross Margin
71.1%
Latest Quarter
Free Cash Flow
$667654000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HALO Overvalued?
Given that Halozyme is profitable, the PE ratio is the primary valuation metric. The trailing PE is 25.5x, while the forward PE is 8.6x, a significant gap that implies the market expects a substantial increase in earnings, likely due to the anticipated growth from royalty streams and new product launches. The forward PE of 8.6x is remarkably low for a biotech with 42% revenue growth, suggesting the stock may be undervalued relative to its growth prospects. Compared to the industry average, Halozyme's PS ratio of 5.77x is below the biotech sector average of around 8-10x, indicating a discount. Its EV/Sales of 7.8x is also moderate, while the EV/EBITDA of 17.6x is reasonable given the high margins. Historically, the stock's PE has ranged from as low as 6.6x (Q3 2021) to as high as 68.8x (Q2 2022), with the current trailing PE of 25.5x sitting near the middle of that range. The forward PE of 8.6x is near the lower end of historical forward multiples, suggesting that the market is pricing in conservative estimates, which could offer upside if the company delivers on its growth targets.
PE
25.5x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 7x~33x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include the company's reliance on a limited number of partnered products for royalty revenue, with DARZALEX being a major contributor. A decline in sales of these drugs or changes in partnership terms could materially impact revenue. The Q4 2025 net loss of -$141.6 million due to an impairment highlights the potential for non-cash charges that can erode earnings and investor confidence. While the balance sheet is solid with a current ratio of 4.66, the debt-to-equity ratio of 43.9% indicates moderate leverage, and any increase in debt to fund growth could raise financial risk. Additionally, the company's high gross margin of 71% is attractive, but it also means that any cost pressures or pricing changes could have a disproportionate impact on profitability.
FAQ
The key risks of holding HALO include: 1) Financial risk: The Q4 2025 net loss of -$141.6 million due to an impairment highlights the potential for non-cash charges that can impact earnings. 2) Competitive risk: The company relies on a limited number of partnered products, and any loss of a major partner like Johnson & Johnson (DARZALEX) could significantly reduce revenue. 3) Macro risk: With a beta of 0.848, the stock is somewhat correlated with the market, and a broader biotech sell-off could drag the price down. 4) Company-specific risk: The high short ratio of 6.68 indicates that some investors are bearish, which could lead to volatility. The most severe risk is a combination of these factors, which could push the stock down to the 52-week low of $61.23, representing a 28.6% downside from the current price.
The 12-month forecast for HALO is based on three scenarios. The bull case (30% probability) targets $90-$96, driven by sustained 40%+ revenue growth and new partnerships. The base case (50% probability) targets $82-$90, with the stock trading near the average analyst target of $86.89. The bear case (20% probability) targets $70-$75, if growth decelerates or partnerships falter. The most likely scenario is the base case, which assumes continued growth at a slightly slower pace. The key assumption is that revenue growth remains above 30% and margins stay above 70%. Investors should monitor quarterly earnings and partnership announcements to gauge which scenario is unfolding.
Based on the analysis, HALO appears undervalued relative to its growth prospects. The forward PE of 8.6x is significantly lower than the trailing PE of 25.5x, indicating that the market expects substantial earnings growth. Compared to the biotech sector average PS ratio of 8-10x, HALO's PS ratio of 5.77x is a discount. Historically, the stock's PE has ranged from 6.6x to 68.8x, and the current forward PE is near the lower end, suggesting the market is pricing in conservative estimates. This implies that if the company delivers on its growth targets, the stock could re-rate higher. The market is not fully pricing in the potential of the ENHANZE technology and the expanding partnership pipeline.
HALO is a good buy for investors with a growth-oriented portfolio and a moderate risk tolerance. The stock offers a compelling risk/reward profile, with a forward PE of 8.6x and 42% revenue growth, suggesting significant upside potential. However, the average analyst target price of $86.89 is only 1.3% above the current price, indicating limited near-term upside. The biggest downside risk is a slowdown in royalty revenue or a setback in key partnerships, which could lead to a decline toward the 52-week low of $61.23. For long-term investors, the low forward PE and strong cash flow make it an attractive holding, but it may not be suitable for those seeking immediate gains or low volatility.
HALO is more suitable for long-term investment due to its growth stage and earnings visibility. The company is in a high-growth phase, with revenue growing 42% YoY, and the forward PE of 8.6x suggests that the market expects continued earnings expansion. The stock has a beta of 0.848, indicating moderate volatility, and no dividend, so it is not suitable for income investors. For short-term traders, the stock's proximity to its 52-week high and the modest analyst upside may limit immediate gains. A minimum holding period of 3-5 years is recommended to allow the ENHANZE technology to reach its full potential and for the market to recognize the company's value. Long-term investors could benefit from the compounding effect of revenue growth and share repurchases.
